Quality of life in patients with advanced gastric cancer: a randomized trial comparing docetaxel, cisplatin and 5-fluorouracil against epirubicin, cisplatin and 5-fluorouracil

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN83369741

Enrollment

Registered

2006-07-28

Start date

2002-01-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric cancer Cancer Gastric cancer

Interventions

Three to six cycles of either ECF (epirubicin 60 mg/m^2, cisplatin 60 mg/m^2 and 5-FU 750 mg/m^2/day as a five-day continuous infusion) or TCF regimen (docetaxel 60 mg/m^2, cisplatin 60 mg/m^2 and 5FU

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with histologically confirmed advanced gastric cancer

Exclusion criteria

Exclusion criteria: Patients with local or local- regional gastric cancer

Design outcomes

Primary

Measure	Time frame
Response rate	—

Secondary

Measure	Time frame
Quality of life and survival	—

Countries

Iran

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026